B. Metzler seel. Sohn & Co. Holding AG Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 9,280 shares of the company's stock, valued at approximately $3,098,000.

Other institutional investors have also recently added to or reduced their stakes in the company. O Shaughnessy Asset Management LLC acquired a new position in shares of Medpace during the first quarter worth about $307,000. Natixis purchased a new position in Medpace in the 1st quarter worth approximately $727,000. MQS Management LLC acquired a new stake in Medpace in the first quarter valued at approximately $318,000. EntryPoint Capital LLC purchased a new stake in shares of Medpace during the first quarter valued at approximately $54,000. Finally, CreativeOne Wealth LLC purchased a new stake in shares of Medpace during the first quarter valued at approximately $1,304,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Up 3.5 %

NASDAQ:MEDP opened at $326.09 on Thursday. The company has a market cap of $10.13 billion, a PE ratio of 28.55, a P/E/G ratio of 1.74 and a beta of 1.37. The business's 50 day moving average is $340.48 and its two-hundred day moving average is $373.99. Medpace Holdings, Inc. has a 52 week low of $268.80 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business's revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.22 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Redburn Atlantic began coverage on shares of Medpace in a research note on Monday, October 14th. They issued a "buy" rating and a $404.00 target price for the company. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Medpace from $395.00 to $336.00 and set a "hold" rating for the company in a research report on Wednesday, July 24th. TD Cowen dropped their target price on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and reduced their price target for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. Finally, Robert W. Baird lowered Medpace from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $413.00 to $349.00 in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $380.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.